A Pilot Pharmacodynamic Study to Assess the Anti-proliferative Activity a of the Poly ADP Ribose Polymerase (PARP) Inhibitor Olaparib in Patients With Human Papilloma Virus (HPV) Positive and Human Papilloma Virus (HPV) Negative Head and Neck Squamous Cell Carcinoma (HNSCC)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 22 Jan 2018
At a glance
- Drugs Olaparib (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Pharmacodynamics
- 11 Jan 2018 Planned End Date changed from 1 Jul 2017 to 1 Jul 2019.
- 11 Jan 2018 Planned primary completion date changed from 1 Jul 2017 to 1 Jan 2019.
- 11 Jan 2018 Planned initiation date changed from 1 Dec 2016 to 1 Jan 2016.